Drug Profile
TAK1
Alternative Names: TAK1 - X-RxLatest Information Update: 28 Sep 2020
Price :
$50
*
At a glance
- Originator X-Rx
- Class Antineoplastics; Small molecules
- Mechanism of Action MAP kinase kinase kinase 7 modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Cancer; Inflammation
Most Recent Events
- 28 Sep 2020 No recent reports of development identified for research development in Cancer in USA
- 28 Sep 2020 No recent reports of development identified for research development in Inflammation in USA
- 05 Aug 2016 TAK1 is available for licensing as of 05 Aug 2016. http://www.x-rxdiscovery.com/